Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 211Triple Negative Breast Neoplasms 32Stomach Neoplasms 32Inflammatory Breast Neoplasms 21Esophageal Neoplasms 16Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Lymphoma 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2

Interventions

temsirolimus 1tegafur-gimeracil-oteracil 1S 1 (combination) 1Oxaliplatin 1Epirubicin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patients With Advanced or Metastatic Solid Tumors × Epirubicin × Clear all
NCT02867397 2016-08-15

Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors

Disphar International B.V.

Phase 1 Completed
25 enrolled
Other solid neoplasm

Patients With Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡